A detailed history of Royal Bank Of Canada transactions in Alector, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 9,970 shares of ALEC stock, worth $39,481. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,970
Previous 8,340 19.54%
Holding current value
$39,481
Previous $37,000 24.32%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.34 - $6.58 $7,074 - $10,725
1,630 Added 19.54%
9,970 $46,000
Q2 2024

Aug 14, 2024

BUY
$4.19 - $6.23 $22,542 - $33,517
5,380 Added 181.76%
8,340 $37,000
Q1 2024

Nov 05, 2024

SELL
$5.69 - $8.08 $30,612 - $43,470
-5,380 Reduced 64.51%
2,960 $17,000
Q1 2024

May 15, 2024

SELL
$5.69 - $8.08 $110,482 - $156,889
-19,417 Reduced 86.77%
2,960 $17,000
Q4 2023

Feb 14, 2024

BUY
$3.77 - $8.39 $50,484 - $112,350
13,391 Added 149.02%
22,377 $178,000
Q3 2023

Nov 14, 2023

BUY
$5.2 - $8.77 $20,300 - $34,238
3,904 Added 76.82%
8,986 $58,000
Q2 2023

Aug 14, 2023

BUY
$5.86 - $7.93 $2,408 - $3,259
411 Added 8.8%
5,082 $30,000
Q1 2023

May 15, 2023

SELL
$5.85 - $9.84 $27,097 - $45,578
-4,632 Reduced 49.79%
4,671 $28,000
Q4 2022

Feb 14, 2023

BUY
$6.88 - $9.55 $50,939 - $70,708
7,404 Added 389.89%
9,303 $85,000
Q3 2022

Nov 14, 2022

BUY
$8.19 - $13.2 $3,325 - $5,359
406 Added 27.19%
1,899 $18,000
Q2 2022

Aug 15, 2022

SELL
$7.65 - $14.24 $24,763 - $46,094
-3,237 Reduced 68.44%
1,493 $15,000
Q1 2022

May 16, 2022

SELL
$13.02 - $20.78 $119,549 - $190,801
-9,182 Reduced 66.0%
4,730 $68,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $25.54 $152,845 - $201,740
7,899 Added 131.37%
13,912 $288,000
Q3 2021

Nov 15, 2021

BUY
$21.65 - $39.49 $16,172 - $29,499
747 Added 14.19%
6,013 $138,000
Q2 2021

Aug 16, 2021

BUY
$15.5 - $22.48 $81,623 - $118,379
5,266 New
5,266 $110,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $327M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.